ストックスクリーナーアプリを入手
37.32
0.21%
-0.08
アフターアワーズ：
37.32
前日終値:
$37.40
開ける：
$37.635
24時間の取引高:
10.16M
Relative Volume:
0.84
時価総額：
$164.79B
収益：
$50.91B
当期純損益:
$18.95B
株価収益率:
8.7585
EPS:
4.261
ネットキャッシュフロー:
$1.92B
1週間 パフォーマンス:
-3.81%
1か月 パフォーマンス:
-20.21%
6か月 パフォーマンス:
+0.92%
1年 パフォーマンス:
-36.47%
1日の値動き範囲:
$37.17
$37.65
1週間の範囲:
$37.17
$38.90
52週間の値動き範囲:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
37.32 | 164.79B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Wolfe Research | Peer Perform |
| 2026-03-18 | 開始されました | Bernstein | Outperform |
| 2026-03-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-03-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | ダウングレード | Goldman | Buy → Neutral |
| 2026-02-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2026-02-24 | ダウングレード | Kepler | Buy → Hold |
| 2026-02-23 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2026-02-12 | アップグレード | Jefferies | Underperform → Hold |
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2025-12-08 | ダウングレード | Argus | Buy → Hold |
| 2025-10-27 | 再開されました | Jefferies | Underperform |
| 2025-10-01 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-09-29 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-09-16 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-31 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-07-30 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-04-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | アップグレード | Kepler | Hold → Buy |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
Eli Lilly vs. Novo Nordisk: valuation gap and pairs trade framework - Investing.com
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections - Zacks Investment Research
Novo Nordisk A/S Sponsored ADR Class B Earnings and Revenue – HAN:NOVA - TradingView
NOVA Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk Weighs Direct NYSE Listing as U.S. Investors Push for Closer Access - finance.biggo.com
Novo Nordisk Is Open To A Direct NYSE Listing - Finimize
Novo Nordisk CEO opens the door to major move for U.S. investors - thestreet.com
Novo Nordisk open to direct NYSE listing, CEO s... - Pluang
Novo CEO Considering Direct Shares Listing: Report - Pharmaceutical Executive
Novo Nordisk Open to Direct NYSE Listing, CEO Tells FT - Global Banking & Finance Review
Key facts: NOVO_B: DKK150bn Plan; Mixed CagriSema, Oral Wegovy Sales - tradingview.com
Novo wants to change how Wall Street owns its stock: why now - Invezz
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT By Reuters - Investing.com
Novo Nordisk stock falls sharply as Capital Markets Day disappoints investors - AD HOC NEWS
Novo's Cardiometabolic Business Is Concentrated in Semaglutide, but the Pipeline Is Growing - Morningstar
European ADRs Started The Week Higher In US Trading - Finimize
Novo Nordisk Stock Slides 8% as $23 Billion Pipeline Goal Leaves a 2032 Gap - TechStock²
Novo Nordisk ADR shares tumble over 7% on Wall Street as long-term plan fails to impress investors - upstox.com
Novo-Nordisk stock heads into the open after a 0.1 percent gain - AD HOC NEWS
Novo Nordisk stock reacts to CHMP backing for FREHEMGO and Novo rebranding - AD HOC NEWS
Novo Nordisk stock gains as analysts see up to 50 percent upside - AD HOC NEWS
Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A - Finansavisen
Novo Nordisk stock heads into the open after a 2.1% slide - AD HOC NEWS
Novo Nordisk stock falls as rebrand to Novo meets cautious analyst response - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk stock extends buyback as trial updates and obesity growth shape outlook - ad-hoc-news.de
Novo Nordisk (NYSE: NVO) has bought back 32M shares, with its 12‑month repurchase plan still running - Stock Titan
Novo Nordisk stock heads into the open after a 2.3% slide - AD HOC NEWS
Novo Nordisk stock falls as heart drug trials are halted despite pediatric obesity win - AD HOC NEWS
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Novo Nordisk trial shows semaglutide helped 40% of children - Investing.com
Weekly Recap: Oral Wegovy launch in Germany and DKK8.7077bn buyback - TradingView
Novo Nordisk stock dips as Wegovy pill launch in Germany reshapes obesity market - AD HOC NEWS
European ADRs Push Higher In Wednesday Session Led By ING, IHG, And Novo Nordisk - foreignpolicyjournal.com
From hunger to obesity: Developing world faces growing threat to child health By Reuters - Investing.com
European ADRs Inched Higher As Healthcare Led Gains - Finimize
Novo Nordisk stock reacts to downgrade as oral obesity push advances in Asia - ad-hoc-news.de
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
1.14%
大文字化:
|
ボリューム (24 時間):